We hypothesized that key antiproliferative target genes for the vitamin D receptor (VDR) were repressed by an epigenetic mechanism in prostate cancer cells resulting in apparent hormonal insensitivity. To explore this possibility, we examined nuclear receptor corepressor expression in a panel of nonmalignant and malignant cell lines and primary cultures, and found frequently elevated SMRT corepressor mRNA expression often associated with reduced sensitivity to 1a,25-dihydroxyvitamin D 3 (1a,25(OH) 2 D 3 ). For example, PC-3 and DU-145 prostate cancer cell lines had 1.8-fold and twofold increases in SMRT mRNA relative to normal PrEC cells (Po0.05). Similarly, 10/15 primary tumour cultures (including three matched to normal cells from the same donors) had elevated SMRT mRNA levels; generally NCoR1 and Alien were not as commonly elevated. Corepressor proteins often have associated histone deacetylases (HDAC) and reflectively the antiproliferative action of 1a,25(OH) 2 D 3 can be 'restored' by cotreatment with low doses of HDAC inhibitors such as trichostatin A (TSA, 15 nM) to induce apoptosis in prostate cancer cell lines. To decipher the transcriptional events that lead to these cellular responses, we undertook gene expression studies in PC-3 cells after cotreatment of 1a,25(OH) 2 D 3 plus TSA after 6 h. Examination of known VDR target genes and cDNA microarray analyses revealed cotreatment of 1a,25(OH) 2 D 3 plus TSA cooperatively upregulated eight (outof1176)genes,includingMAPK-APK2andGADD45a. MRNA and protein time courses and inhibitor studies confirmed these patterns of regulation. Subsequently, we knocked down SMRT levels in PC-3 cells using a small interfering RNA (siRNA) approach and found that GADD45a induction by 1a,25(OH) 2 D 3 alone became very significantly enhanced. The same distortion of gene responsiveness, with repressed induction of GADD45a was found in primary tumour cultures compared and to matched peripheral zone (normal) cultures from the same donor. These data demonstrate that elevated SMRT levels are common in prostate cancer cells, resulting in suppression of target genes associated with antiproliferative action and apparent 1a,25(OH) 2 D 3 -insensitivity. This can be targeted therapeutically by combination treatments with HDAC inhibitors.
We hypothesized that key antiproliferative target genes for the vitamin D receptor (VDR) were repressed by an epigenetic mechanism in prostate cancer cells resulting in apparent hormonal insensitivity. To explore this possibility, we examined nuclear receptor corepressor expression in a panel of nonmalignant and malignant cell lines and primary cultures, and found frequently elevated SMRT corepressor mRNA expression often associated with reduced sensitivity to 1a,25-dihydroxyvitamin D 3 (1a,25(OH) 2 D 3 ). For example, PC-3 and DU-145 prostate cancer cell lines had 1.8-fold and twofold increases in SMRT mRNA relative to normal PrEC cells (Po0.05). Similarly, 10/15 primary tumour cultures (including three matched to normal cells from the same donors) had elevated SMRT mRNA levels; generally NCoR1 and Alien were not as commonly elevated. Corepressor proteins often have associated histone deacetylases (HDAC) and reflectively the antiproliferative action of 1a,25(OH) 2 D 3 can be 'restored' by cotreatment with low doses of HDAC inhibitors such as trichostatin A (TSA, 15 nM) to induce apoptosis in prostate cancer cell lines. To decipher the transcriptional events that lead to these cellular responses, we undertook gene expression studies in PC-3 cells after cotreatment of 1a,25(OH) 2 D 3 plus TSA after 6 h. Examination of known VDR target genes and cDNA microarray analyses revealed cotreatment of 1a,25(OH) 2 D 3 plus TSA cooperatively upregulated eight (outof1176)genes,includingMAPK-APK2andGADD45a. MRNA and protein time courses and inhibitor studies confirmed these patterns of regulation. Subsequently, we knocked down SMRT levels in PC-3 cells using a small interfering RNA (siRNA) approach and found that GADD45a induction by 1a,25(OH) 2 D 3 alone became very significantly enhanced. The same distortion of gene responsiveness, with repressed induction of GADD45a was found in primary tumour cultures compared and to matched peripheral zone (normal) cultures from the same donor. These data demonstrate that elevated SMRT levels are common in prostate cancer cells, resulting in suppression of target genes associated with antiproliferative action and apparent 1a,25(OH) 2 D 3 -insensitivity. This can be targeted therapeutically by combination treatments with HDAC inhibitors.
Introduction
Prostate epithelial cells express multiple members of the nuclear receptor (NR) superfamily. These receptors act as ligand-activated transcription factors to regulate genes essential for regulation of proliferation and differentiation. The vitamin D receptor (VDR) typifies this class of transcription factors by associating with vitamin D response elements (VDRE) in the promoter/ enhancer region of target genes as part of multimeric, repressive or activating complexes.
Proliferation and differentiation of normal prostate epithelial cells is acutely regulated in vitro and in vivo by 1a,25(OH) 2 D 3 (Peehl et al., 1994; Konety et al., 1996) , thereby justifying clinical trials in prostate cancer patients (Beer et al., 2003) . However, prostate cancer cells display a spectrum of sensitivities to the antiproliferative action of 1a,25(OH) 2 D 3 (reviewed in Chen and Holick (2003) , Krishnan et al. (2003) and Peehl and Feldman (2003) ). Reflective of an antiproliferative role, epidemiological studies have now linked the incidence of prostate cancer to low serum levels of 25(OH)D 3 as a result of either diet or environment, and specific VDR polymorphisms have been correlated with cancer susceptibility (Hanchette and Schwartz, 1992; Ingles et al., 1998) . Collectively, such data implicate 1a,25(OH) 2 D 3 with a protective action against uncontrolled prostate growth; that initiation or progression of prostate cancer may relate to reduced dietary intake and/or cellular resistance to the antiproliferative effects of 1a,25(OH) 2 D 3 .
The molecular mechanisms for 1a,25(OH) 2 D 3 -insensitivity in prostate cancer are as yet unclear. We and others have demonstrated that the VDR is neither mutated nor is there a clear relationship between VDR expression and growth inhibition by 1a,25(OH) 2 D 3 (Miller et al., 1997; Zhuang et al., 1997) . Indeed, the PC-3 and DU-145 prostate cancer cell lines are not significantly inhibited by physiologically relevant doses of 1a,25(OH) 2 D 3 and consistent with this response, antiproliferative gene targets are not modulated Campbell et al., 2000) . The lack of an antiproliferative response is not reflected by an overall suppression of the capacity of these cells to perceive 1a,25(OH) 2 D 3 . VDR transactivation is sustained or even enhanced, as measured by induction of the highly 1a,25(OH) 2 D 3 -inducible CYP24 gene (encoding 25(OH)D 3 -24-hydroxylase-the 1a,25(OH) 2 D 3 metabolizing enzyme) (Miller et al., 1995) .
To resolve why prostate cancer cells appear to lose sensitivity to the antiproliferative action of 1a,25(OH) 2 D 3 , we have considered epigenetic mechanisms that regulate promoter access. NRs exist in complexes that are in a dynamic balance between the apo, ligand-free state associated with corepressor and the holo, ligand-bound state associated with coactivator (Germain et al., 2002; Hermanson et al., 2002) . In the absence of 1a,25(OH) 2 D 3 , the VDR associates in a gene repression complex that contains corepressor proteins such as NCoR1, SMRT, and Alien, and associated histone deacetylases (HDAC) (Polly et al., 2000; Guenther et al., 2001; Yu et al., 2003) . These complexes maintain the histone N-terminal 'tails' in a charged state tightly associated with DNA, thereby maintaining a locally closed chromatin structure and suppressing transcription of target genes (Guenther et al., 2001; Belandia and Parker, 2003) . Ligand binding induces activation, which has been demonstrated for related NRs to include ordered promoter-specific cyclical rounds of complex assembly, gene transactivation, disassembly, and proteosome degradation of receptor (Metivier et al., 2003; Reid et al., 2003b) . Central to this are ligand-induced conformational changes that promotes association between the VDR and coactivator complexes containing proteins such as SRC-1, NCoA-62, GRIP-1, and DRIP factors Zhang et al., 2001; Belandia and Parker 2003; Oda et al., 2003) . The antagonistic actions of these opposing complexes are controlled temporally and spatially to determine the boundaries between heterochromatin and euchromatin and gene promoter responsiveness.
The cell-specific position of the dynamic balance between apo and holo states is determined by both ligand availability and the unique milieu of coactivator and corepressors, which combine to yield gene-specific responses (Hermanson et al., 2002) . The equilibrium is targeted for disruption in malignancy by aberrant coactivator and corepressor function resulting in both gain and loss of NR function. For example, increased coactivator expression enhances the transcriptional activity of androgens and oestrogens in breast and prostate cancer, respectively (Feldman and Feldman, 2001; Gnanapragasam et al., 2001; Kollara et al., 2001; Planas-Silva et al., 2001; Hudelist et al., 2003; Kawashima et al., 2003; Jiang et al., 2003b) . Similarly, RARafusion proteins in acute promyelocytic leukaemia bind corepressors more aggressively than wild-type receptors and thereby suppress transactivation of antiproliferative target genes by all trans-retinoic acid (Grignani et al., 1998; Lin et al., 1998) .
Therefore, we have proposed that VDR signalling is not abrogated in prostate cancer cells, but it is skewed by epigenetic mechanisms to repress key antiproliferative gene targets. Previously, we showed that cotreatment of three prostate cancer cell lines (LNCaP, PC-3, and DU-145) with 1a,25(OH) 2 D 3 plus HDAC inhibitors, either trichostin A (TSA) or sodium butyrate, resulted in additive and synergistic inhibition of proliferation associated with apoptosis (Rashid et al., 2001a) . For the current study, we hypothesized that an imbalance in the coactivator/corepressor balance is selectively distorting promoter responsiveness of VDR antiproliferative target genes resulting in 1a,25(OH) 2 D 3 -insensitivity. We have now examined VDR and corepressor levels in cell lines and primary cultures, dissected the effects of 1a,25(OH) 2 D 3 plus TSA on gene expression patterns to identify antiproliferative pathways that are suppressed in malignancy, and we have also examined the effects of knocking down SMRT levels using a small interfering RNA (siRNA) approach.
Results

SMRT mRNA levels are elevated in prostate cancer cell lines and primary cultures
We reasoned that cancer cells can escape proliferative control from NRs, such as VDR, by elevating corepressor expression. We therefore measured the mRNA levels of VDR and the nuclear corepressors SMRT, NCoR1, and Alien in primary cultures of cancers (E-CA-1, -2, -3, -4, -5, -6, -9, -10, -11, -12, -15, mean age of 55.5 years), benign prostatic hyperplasia (E-BPH-1, E-BPH-2, mean age of 61 years) compared to the mean of seven normal peripheral zones cultures (E-PZ-1 to -7, mean age of 55 years) (Figure 1a ), three matched tumour and normal pairs from the same donor (E-CA-7, -8, -9 and E-PZ-5, -1, -4 respectively) (Figure 1b) , and LNCaP, PC-3, and DU-145 cancer cell lines and PrEC normal prostate epithelial cells (Figure 1c ). These data are summarized in Table 1 .
Several nonmatched tumour cultures displayed elevated corepressor levels (42-fold elevation) compared to the mean level in the seven normal cultures with SMRT being the most frequently elevated (7/12), with NCoR1 and Alien less frequently elevated (two and one cultures, respectively). Among the primary cancer cultures and cell lines, there was a trend towards increased SMRT mRNA levels in the least differentiated and/or androgen-independent cells. Thus, two out of six cancer cultures with Gleason score of 3/3 had elevated SMRT mRNA, while three out of four cultures with Gleason score of 4/3 and greater had elevated SMRT. Similarly, both androgen-insensitive cell lines had elevated SMRT (Table 1) . Despite the relatively large spread of the fold-differences, changes in SMRT in all primary cancer cultures (0.4-31.6), compared to the normal cultures, the mean ddC t for the cancer cultures (where reduced ddC t values indicate elevated target gene mRNA transcript) was 9.9272.004 (s.d.) compared to the normal, which was 11.2871.02 (s.d.), reflecting the reduced variation in levels in the normal peripheral zone cultures (Figure 1a) . These data were supported by the matched cancer and peripheral zone normal cultures, each pair from the same donor, in which all cancers displayed elevated SMRT mRNA compared to the normal counterpart elevation (42-fold) (Figure 1b) . Interestingly, the spread of SMRT levels in all cancer cultures samples correlated very strongly with those of VDR (r ¼ 0.85, Po0.0001). A similar elevation in SMRT mRNA levels was observed in PC-3 and DU-145 cells ((1.8-fold (Po0.05) and 2.2-fold (Po0.05)), respectively, compared to PrEC cells (Figure 1c ). The levels of SMRT did not correlate with VDR, as seen in the primary cancer cultures tumours, and all cancer cell lines had a significant reduction in the VDR expression compared to PrEC cells.
We compared these expression patterns with sensitivity to the antiproliferative actions of 1a,25(OH) 2 D 3 in primary cultures and cell lines ( Table 1 ). The two assays measure related aspects of cellular responses to 1a,25(OH) 2 D 3 . The ATP proliferation assay measures total cellular ATP after 4 days, while the colony assay measures growth of cells after 10 days by measuring the total mass of cells (protein) per dish. In previous studies, we have established that both of these readouts are proportional to cell number and thus these assays, while different, are readily comparable (Peehl et al., 1994; Rashid et al., 2001a) . Reflective of this, the ED 50 values of normal cultures in the two assays were comparable, which we attribute to 1a,25(OH) 2 D 3 having a pleiotropic set of actions regulating both cell cycle progression, proliferation and invasion (Blutt et al., 1997 (Blutt et al., , 2000 Schwartz et al., 1997; Polek et al., 2003) . Elevated SMRT in PC-3 and DU-145 correlated with their insensitivity to 1a,25(OH) 2 D 3 (ED 50 4100 nM). The same diversity of responsiveness was seen in a representative panel of primary cancer cultures compared to normal, and BPH cultures. For example, in colony formation assays, the benign culture (E-BPH#1) had ED 50 ¼ 0.2 nM, which was comparable with the responses of the normal strains we have characterized previously (Peehl et al., 1994) , whereas the cancer cultures displayed a spectrum of sensitivities. This spectrum is typified by the cancer culture E-CA-7, where the cancer culture is insensitive to 1a,25(OH) 2 D 3 (ED 50 4100 nM), whereas its matched normal counterpart (E-PZ-5) is acutely sensitive (ED 50 ¼ 5 nM). Taken together, these data suggest that resistance of prostate -2, -3, -4, -5, -6, -9, -10, -11, -12, -15 , mean age of 55.5 years), benign prostatic hyperplasia (E-BPH-1, E-BPH-2, average age 61 years) compared to the mean of seven normal peripheral zones cultures (E-PZ-1 to -7, mean age of 55 years). Total mRNA was isolated from cultures in mid-exponential phase, reverse transcribed and the target genes amplified in triplicate according to Materials and methods. Panel b: VDR and corepressor mRNA levels measured by Q-RT-PCR in three matched cancer (E-CA-7, E-CA-8, and E-CA-14) compared to three normal matched peripheral zone cultures (E-PZ-5, E-PZ-1, and E-PZ-4, respectively) as above. The PrEC cells proliferate at approximately the same rate as the PC-3 cancer cells, and yet PrEC cells display a very different and acute response to the antiproliferative action of 1a,25(OH) 2 D 3 (Figure 2a and b). We used PC-3 cells, as a 1a25(OH) 2 D 3 -insensitive cell line with increased corepressor expression, to measure the effect of HDAC activity on the antiproliferative sensitivity to 1a25(OH) 2 D 3 . Control cultures of PC-3 and PrEC cells had comparable dose-response sensitivities to treatment with TSA alone (data not shown) and, therefore, we examined the effects on proliferation of a minimally active dose of TSA (15 nM) alone and cotreatment together with escalating doses of 1a25(OH) 2 D 3 . The acute inhibition of proliferation of PrEC cells by 1a25(OH) 2 D 3 alone was only affected by TSA when exposed to low doses of 1a,25(OH) 2 D 3 (0.01 nM) ( Figure 2a ). By contrast, in PC-3 cells the cotreatment resulted in strong additive effects with 100 nM 1a,25(OH) 2 D 3 and additive effects at 10 and 1 nM ( Figure 2b ); this effectively reinstated the antiproliferative response of PC-3 cells to levels that were comparable to PrEC cells. These data reflect our previous data obtained in prostate cancer cell lines at a single dose of 1a,25(OH) 2 D 3 in both liquid and semisolid proliferation assays (Rashid et al., 2001a) .
Regulation of VDR and CYP24 in PC-3 cells cotreated with agents
To examine the transcriptional effects of the cotreatment of agents, we examined the induction of VDR and CYP24. The CYP24 gene is among the best characterized and most profoundly regulated VDR target gene (Dwivedi et al., 2000) . We and others have shown in prostate and breast cancer and leukaemia cell lines that CYP24 is modulated in a manner that is broadly inversely proportional to the antiproliferative action of 1a25(OH) 2 D 3 , and is in part responsible for regulating cellular sensitivity to 1a25(OH) 2 D 3 (Miller et al., 1995; Ly et al., 1999; Rashid et al., 2001b) . Similarly, in the current study, we found exuberant tumour-enhanced CYP24 induction in primary cancer cultures treated with 1a,25(OH) 2 D 3 (50 nM, 6 h) ( Figure 3a) . Therefore, we examined CYP24 mRNA expression in PC-3 cells over time.
Treatment with 1a,25(OH) 2 D 3 alone resulted in a rapid and very large upregulation of CYP24 mRNA (6.9-fold by 1 h, Po0.01), which continued throughout the course of the treatment, resulting in the very significant 6600-fold increase seen at 7 h (Po0.0001) (Figure 3b ). By contrast, treatment with TSA alone resulted in a relatively modest effect on expression peaking at 7 h (3.7-fold), but in combination, it very significantly suppressed the 1a,25(OH) 2 D 3 -dependent induction. For example, the mRNA upregulation observed with 1a25(OH) 2 D 3 alone at 7 h was significantly suppressed to a mean fold increase of 1302 (Po0.001). At subsequent time points, the suppressive action of TSA was diminished.
We reasoned that the significant induction of CYP24 was in part the consequence of direct and indirect responses to treatment. To investigate this further, we used the same treatments in the presence and absence of de novo protein synthesis using cycloheximide. A significant reduction in the induction of CYP24 was observed when cycloheximide was added, although this was most pronounced with 1a,25(OH) 2 D 3 alone. Consistent with the time course data, 6 h exposure to 1a,25(OH) 2 D 3 alone resulted in a 3342 mean fold increase (Po0.0001) in CYP24 mRNA expression ( Figure 3c ). However, this was greatly and significantly suppressed (Po0.0001) to an 85-fold increase in cells cotreated with 1a,25(OH) 2 D 3 and cycloheximide. The effect of 1a,25(OH) 2 D 3 was significantly suppressed further by cotreatment of both cycloheximide and TSA resulting in only a 4.4-fold increase. Taken together, these data suggest a network of transcriptionally regulated cofactors that act in concert to modify the responses to 1a,25(OH) 2 D 3 . This does not appear to include the receptor as there were no significant effects on VDR expression with either single or combined treatments over the same 12 h time course (data not shown).
Identification and regulation of genes in PC-3 cells cotreated with 1a25(OH) 2 D 3 plus TSA
To characterize more fully the transcriptional effects of the cotreatment of agents, we undertook cDNA microarray analyses in PC-3 cells. A number of genes were identified that have been demonstrated to be targets for these agents by other workers. A wellknown established VDR target gene is the CDKI, p21 (waf1/cip1) (Liu et al., 1996) , and supportively this was modulated in the 1a25(OH) 2 D 3 -alone treatment group (2.1-fold); however, this was unaffected by cotreatment with TSA (data not shown). This supports our previous study that indicated that this gene was not coordinately modulated by the cotreatment of 1a25(OH) 2 D 3 and TSA (Rashid et al., 2001a) . Similarly, TSA at concentrations higher than those used in the current study is a potent inducer of apoptosis (Hirose et al., 2003b; Yamashita et al., 2003) , and in the current study we found Bcl-2 downregulated 0.48-fold by TSA treatment alone, which was unaffected by the cotreatment (data not shown).
For subsequent studies, we focused on genes that appeared to be coordinately regulated by the combined treatments, and have established roles in regulating proliferation, differentiation, and apoptosis. We identified eight genes (out of 1176) that demonstrated cooperative, additive increases in expression after 6 h exposure to combined TSA and 1a25(OH) 2 D 3 (Table 2) . These genes included those that have roles in controlling apoptosis and proliferation (GADD45a (Jin et al., 2001) (Table 2 ). From our preliminary validation studies, we chose to focus on MAPK-APK2 and GADD45a as these have been shown to be gene targets for NR action (Wang et al., 2000; Akutsu et al., 2001; Alsayed et al., 2001) . Real-time reverse transcription-polymerase chain reaction (RT-PCR) over a 12 h time course in PC-3 cells confirmed that MAPK-APK2 mRNA was readily detected in control cells, reflecting the relatively strong control signal on the cDNA microarray, and was significantly higher than GADD45a mRNA levels (11.4-fold greater, P&lt;0.001). This was reflected by the lack of a basal GADD45a signal detected on the cDNA microarray, and hence no fold change could be calculated (Table 2 ). 1a,25(OH) 2 D 3 alone had limited effect on MAPK-APK2 mRNA expression with a modest 1.3-fold increase after 6 h ( Figure 4a ). In contrast, TSA alone produced an acute induction of 2.3-fold increased mRNA expression at 4 h (Po0.001). Cotreatment with 1a,25(OH) 2 D 3 and TSA resulted in a sustained window of MAPK-APK2 upregulation, which was maintained for several hours to approximately 8 h post-treatment ( Figure 4a ). SB203580 is a highly specific inhibitor of p38 that blocks the activation of MAPK-APK2. Importantly, SB203580 had no effect on cell growth when used alone or in combination with either agent separately ( Figure 4b and data not shown), but abrogated the capacity of TSA to sensitize PC-3 cells to the antiproliferative actions of 1a,25(OH) 2 D 3 (Figure 4b ). Taken together, these data suggest that the antiproliferative activity of combined TSA plus 1a,25(OH) 2 D 3 is dependent on the sustained re-expression and activation of MAPK-APK2.
In some respects, the pattern of GADD45a mRNA expression in response to 1a,25(OH) 2 D 3 mirrored that of MAPK-APK2. 1a,25(OH) 2 D 3 alone resulted in the steady accumulation of GADD45a mRNA after 3 h, Regulation of CYP24 in response to 1a,25(OH) 2 D 3 (100 nM) and TSA (15 nM) either alone or in combination. In total, 2 Â 10 4 /cm 2 cells plated into six-well plates and allowed to grow for 36 h to ensure that cells were in mid-exponential phase. Total RNA was isolated after the indicated time periods, reverse transcribed and CYP24 amplified according to Materials and methods. Each data point represents the mean of three separate experiments amplified in triplicate wells. The 1a,25(OH) 2 D 3 treatment was significantly greater than any other at all time points as indicated. Combined treatments that were significantly less than 1a,25(OH) 2 D 3 treatment are indicated: *Po0.05, **Po0.001, ***Po0.0001, ****P50.0001. Panel c: Real-time RT-PCR was used to measure the regulation CYP24 in response to 1a,25(OH) 2 D 3 (100 nM) and TSA (15 nM) either alone or in combination, in the presence or absence of cycloheximide (CHX, 20 mg/ml). Triplicate sets of 2 Â 10 4 /cm 2 cells were plated into six-well dishes and allowed to grow for 36 h. Total RNA was isolated after 6 h of exposure to the indicated treatments, reverse transcribed and the target genes were amplified according to Materials and methods. Each data point represents the mean of three separate experiments undertaken amplified in triplicate wells. Combined treatments that were significantly greater than either agent alone, and the effect of CHX, are indicated: *Po0.05, **Po0.001, ***Po0.0001 peaking at 2.4-fold increase relative to control. TSA induction occurred between 4 and 6 h post treatment with a significant mean fold increase compared to control of 3.1 after 4 h (Po0.0001) (Figure 5a ). However, as in the case of MAPK-APK2, the combined treatment sustained a window of increased expression at a level that was higher than the peak responses to either treatment alone (for example, 1a,25(OH) 2 D 3 1.0-fold, TSA 1.6-fold and cotreatment 4.3-fold, at 7 h). Consistent with this sustained pattern of mRNA expression, Western immunoblot analysis confirmed the increased expression of GADD45a protein most clearly following 9 h of exposure to combined 1a,25(OH) 2 D 3 and TSA, but not to either agent alone. A representative figure is shown in Figure 5b , where the fold increase in agents was equal to a mean 2.4-fold increase, whereas the single treatments had only modest fold increases (o1.5). Data at earlier time points did not show cooperative changes in protein (data not shown).
Targeted silencing of SMRT with siRNA
To support further the central role of SMRT in distorting transcriptional effects and therefore the antiproliferative actions of 1a,25(OH) 2 D 3 , we used the siRNA approach to reduce SMRT mRNA in PC-3 cells. The quantitative RT-PCR (Q-RT-PCR) primers and probes that detected SMRT mRNA levels were 3 0 of the region targeted by the SMRT siRNA and therefore we were able to measure the effects of siRNA treatment at the mRNA level. These studies resulted in a mean 0.04-fold reduction in SMRT mRNA levels at 72 h posttreatment (Figure 6a ). Cells were then dosed with 1a,25(OH) 2 D 3 and the induction of GADD45a measured. Supportively in cells where SMRT levels were reduced, but not mock treated (GFP) cultures, GADD45a became very highly responsive to 1a,25(OH) 2 D 3 treatment (Figure 6b ).
Dysregulation of VDR target genes in matched primary cultures
To examine the significance of the differential gene responsiveness observed in PC-3 cells, we examined CYP24 and GADD45a mRNA induction in response to 1a,25(OH) 2 D 3 treatment (50 nM, for 6 h) in three primary tumour cultures (E-CA-7, E-CA-8, and E-CA-14) compared to their matched peripheral zone cultures (E-PZ-5, E-PZ-1, and E-PZ-4, respectively). Initially, we characterized the basal expression of the VDR, the three corepressors and the target genes CYP24 and GADD45a. All three tumour cultures displayed elevated SMRT compared to their matched normal counterpart, and in cultures E-CA-7 and E-CA-14 this was matched by elevated VDR levels (Figure 1b ). E-CA-7, E-CA-8, and E-CA-14 cultures displayed repressed levels of GADD45a relative to their matched normal controls (0.5-, 0.02-, and 0.09-fold decrease, respectively). This was complemented by elevated basal levels of CYP24 in the E-CA-7 and E-CA-14 cultures of 3.2-and 2.3-fold, respectively. Subsequently, we examined the regulation of CYP24 and GADD45a in response to 1a,25(OH) 2 D 3 (50 nM) (Figure 7a and b) . Upon treatment with 1a,25(OH) 2 D 3 , the tumour cultures displayed distorted responses with simultaneous enhancement of CYP24 and repression of GADD45a induction. CYP24 induction in the E-CA-7 cancer primary culture was approximately twice that seen in the normal counterpart peripheral zone (984-and 567-fold, respectively); enhancement of induction was also seen in the E-CA-8 and E-CA-14. By contrast, GADD45a was not modulated in the tumour culture but was 2.6-fold in the peripheral zone normal cells (E-PZ-5). Similar dysregulation was seen in the other matched cultures. Interestingly, E-CA-7 was essentially insensitive to 1a,25(OH) 2 D 3 (ED 50 4100 nM), whereas its normal counterpart E-PZ-5 was acutely responsive (Table 1) . Taken together, these data support the Table of fold differences (Fold) and change in the mean adjusted intensity (DMAI) for target genes that were cooperatively regulated by the cotreatment of agents, compared to control. From each of the treatments, the fold and DMAI was calculated from the mean of the two experiments. Only genes that were reported as modulated in the same manner in both experiments were included in the results. Repeat experiments involved stripping the membranes (which were checked to ensure zero signal) and reprobing with radiolabelled probes prepared from repeat treatments of cells [2] Nc, fold change not calculated concept of elevated SMRT corepressor levels resulting in promoter-specific distortions of transcriptional responsiveness leading to apparent insensitivity towards 1a,25(OH) 2 D 3 .
Discussion
The active metabolite of vitamin D, 1a,25(OH) 2 D 3 , is readily able to initiate gene transactivation and acutely regulate proliferation of normal prostate, breast, and colon epithelial cells and myeloid CD 34-positive precursors (Konety et al., 1996; Ratnam et al., 1996; Tong et al., 1998; Rashid et al., 2001b; Zinser et al., 2002) . By contrast, cancer and leukaemic cell lines from these tissues display a spectrum of sensitivities including complete insensitivity to 1a,25(OH) 2 D 3 , irrespective of VDR expression (Munker et al., 1986; Campbell et al., 1997; Kubota et al., 1998; Palmer et al., 2001) . The central hypothesis of the current study is that this apparent hormonal insensitivity is not determined solely by a linear relationship between the levels of Panel a: Q-RT-PCR was used to measure the regulation of MAPK-APK2 in response to 1a,25(OH) 2 D 3 (100 nM) and TSA (15 nM) either alone or in combination. In total, 2 Â 10 4 /cm 2 cells were plated into six-well dishes and allowed to grow for 36 h to ensure that cells were in mid-exponential phase. Total RNA was isolated after the indicated time periods, reverse transcribed and MAPK-APK2 amplified according to Materials and methods. Each data point represents the mean of three separate experiments amplified in triplicate wells. Combined treatments that were significantly greater than either agent alone are indicated: *Po0.05. Panel b: PC-3 were plated into 96-well plates (2 Â 10 3 / well) cells and treated with either 1a,25(OH) 2 D 3 (100 nM), TSA (15 nM) or SB203580 (10 mM) either alone or in combination. After 96 h, with a redose after 48 h, total ATP was measured using a luciferase-dependent method according to Materials and methods and compared to untreated control, as a marker of proliferation. Each data point represents the mean7s.e.m. values of three separate experiments undertaken in triplicate wells. 1a,25(OH) 2 D 3 plus TSA plus SB203580 is significantly less inhibitory than 1a,25(OH) 2 D 3 plus TSA (*Po0.05) Figure 5 Regulation of GADD45a mRNA and protein in PC-3 cells. Panel a: Q-RT-PCR was used to measure the regulation of GADD45a mRNA in response to 1a,25(OH) 2 D 3 (100 nM) and TSA (15 nM) either alone or in combination. In total, 2 Â 10 4 /cm 2 cells were plated into six-well dishes and allowed to grow for 36 h to ensure that cells were in mid-exponential phase. Total RNA was isolated after the indicated time periods, reverse transcribed and GADD45a amplified according to Materials and methods. Each data point represents the mean of three separate experiments amplified in triplicate wells. Combined treatments that were significantly greater than either agent alone are indicated: *Po0.05. Panel b: Parallel T75 flasks seeded at the same density were exposed to 1a,25(OH) 2 D 3 (100 nM) and TSA (15 nM) either alone or in combination and total protein was isolated after 9 h. Expression of GADD45a was determined by Western immunoblot analysis. The position of GADD45a is indicated at the left of the panel. Blots were subsequently stripped and reprobed for b-actin 1a,25(OH) 2 D 3 and the VDR, but rather epigenetic events skew the responsiveness to suppress responsiveness of target gene promoters selectively.
We found frequently elevated corepressor expression, most commonly involving SMRT, in malignant primary cultures and cell lines, with reduced 1a,25(OH) 2 D 3 antiproliferative response, but not normal or BPH cultures, indicating that the ratio of VDR to corepressor is a more critical indicator of malignant status and 1a,25(OH) 2 D 3 responsiveness. We explored the significance of elevated corepressor levels in both cancer cell lines and primary cultures. We reasoned that this lesion could be targeted by cotreatment of ligand (1a,25(OH) 2 D 3 ) plus HDAC inhibitor (TSA) and supportively demonstrated that the 1a,25(OH) 2 D 3 -response of the androgen-independent PC-3 cells was restored to levels indistinguishable from control PrEC cells, by cotreatment with low doses of TSA. This reversal of 1a,25(OH) 2 D 3 insensitivity provided the opportunity to examine patterns of global acetylation and expression of target genes.
In preliminary studies, we have examined the global histone acetylation status after cotreatment by extraction of total cellular histone from cells treated by single and combination treatments, and resolution on acid urea triton gels (Sommerville et al., 1993) . The relatively low dose of TSA used (15 nM) readily increased global histone acetylation, that is, acetylation at all lysine residues examined (Histone H4 Lys shown) despite its ability to induce a comparable number of genes. The combined treatment did not alter global acetylation beyond the effect of TSA alone. Collectively, these data suggest that differences between global acetylation patterns do not reflect promoterspecific gene transcription. Microarray studies demonstrated that 1a,25(OH) 2 D 3 plus TSA uniquely upregulated a group of 'repressed' gene targets associated with the control of proliferation and induction of apoptosis. GADD45a initiates cell cycle arrest, to facilitate DNA repair or apoptosis dependent upon the p53 status (Jin et al., 2001 (Jin et al., , 2003 ; upregulation of GADD45a when p53 function is abrogated induces a predominant apoptotic response (Jin et al., 2003) . p53 function is abrogated in PC-3 cells and we have reported previously that cotreatment with 1a,25(OH) 2 D 3 and TSA in these cells results in apoptosis, in the absence of any significant cell cycle changes (Rashid et al., 2001a) . Recently, TSA has also been shown to induce GADD45a mRNA by a combination of stabilization of transcription factors such as Oct1 on the promoter region (Hirose et al., 2003a) , and thus in the current study this may well enhance further the activities of the VDR.
Roles for both GADD45a and MAPK-APK2 have been demonstrated in cell lines that retain sensitivity to 1a,25(OH) 2 D 3 signalling. For example, p38/MAPK-APK2 activation regulates 1a25(OH) 2 D 3 -induced HL-60 myeloid differentiation (Wang et al., 2000) and upregulation of GADD45a is a functional part of the antiproliferative action of EB1089 (an analogue of 1a,25(OH) 2 D 3 ) in SCC25 squamous carcinoma cells (Akutsu et al., 2001 ) and 1a,25(OH) 2 D 3 in ovarian cancer cell lines (Jiang et al., 2003a) . These studies and our own re-expression data highlight these targets as key in mediating the antiproliferative action of 1a,25(OH) 2 D 3 . The siRNA approach demonstrated the significant role that SMRT plays in regulating this response, with its repression resulting in profound enhancement of the induction of GADD45a in response to 1a,25(OH) 2 D 3 . These data support a central role for elevated SMRT levels in suppressing the induction of key target genes resulting in loss of sensitivity to the antiproliferative action of 1a,25(OH) 2 D 3 .
Target gene induction was measured by time course studies using highly sensitive Q-RT-PCR, which revealed distinct and relatively acute increases and decreases in mRNA levels. Cotreatment of 1a,25(OH) 2 D 3 plus TSA generates temporal windows where the equilibrium point of gene transactivation is shifted to favour a more transcriptionally permissive environment. This is limited by a number of processes including the NR proteosomic turnover (Reid et al., 2003a) and the metabolism of both agents (Yoshida et al., 1995) . The induction of CYP24, which encodes the 1a,25(OH) 2 D 3 -metabolizing enzyme 25(OH)D 3 -24-hydroxylase, is suppressed by the cotreatment and thus one contributory factor to the increased antiproliferative potency of the combination of 1a,25(OH) 2 D 3 plus TSA treatment may be the greater availability of 1a,25(OH) 2 D 3 . However, CYP24-resistant analogs of 1a,25(OH) 2 D 3 are not as inhibitory as 1a,25(OH) 2 D 3 plus TSA, and in turn, we have demonstrated that their potency can be enhanced further by cotreatment with TSA (Rashid et al., 2001a) . Thus, although ligand availability may be elevated, chromatin remodelling to allow VDR access to other promoters appears more influential.
Suppression of promoter responsiveness is target gene-specific as exuberant induction of CYP24 occurred in PC-3 cells despite a suppression of GADD45a and MAPK-APK2 response. Similarly, the microarray analyses also identified a group of 39 genes modulated readily by 1a,25(OH) 2 D 3 alone, many of which had no clear antiproliferative function, such as Cyclin B1, CMyc, MCM7 DNA replication licensing factor and PCNA. Furthermore, cotreatment with TSA suppressed the upregulation of CYP24 and many of the 1a,25(OH) 2 D 3 -responsive gene targets. For example, treatment of cells treated with 1a25(OH) 2 D 3 alone resulted in a DMAI with PCNA of 20 505, which was suppressed by the addition of TSA to 3954 (data not shown). Intriguingly, cotreatment with cycloheximide suppressed the induction of CYP24; a similar suppression has been observed recently in different cell types (Zierold et al., 2002) . By contrast, upregulation of MAPK-APK2 and GADD45a by TSA and 1a,25(OH) 2 D 3 was unaffected, supporting a direct role for VDR in their regulation. Others have demonstrated a cooperative interaction between VDR and Ets-1 on the CYP24 promoter resulting in stimulation of gene responsiveness by upstream Ras (Dwivedi et al., 2000 (Dwivedi et al., , 2002 . Thus, increased oncogenic Ets signalling may explain the paradoxical enhanced 1a,25(OH) 2 D 3 -dependent upregulation of CYP24 observed in cancer cells, and support the concept that high basal or inducible levels of CYP24 are transforming (Albertson et al., 2000) .
Work in primary prostate cultures has extended beyond cancer cell lines the concept that enhanced corepressor action selectively suppresses the responsiveness of key antiproliferative target gene promoters. We found significant and common elevation of SMRT in tumour cultures, and using matched tumour and normal peripheral zone cultures, we were able to demonstrate the promoter-specific dysregulation of CYP24 and GADD45a observed in the cancer cell lines.
The ability of the VDR target genes to respond differentially reflects both the different arrangements and sequences of VDRE among VDR target genes and the number of different apo and holo complexes, which are assembled upon them. It has been proposed that a specific subset of VDRE (IP9) are more commonly associated with genes that mediate growth arrest and apoptosis (Danielsson et al., 1997; Quack and Carlberg, 1999) . Furthermore, IP-9-type response elements have been shown to associate with the corepressors NCoR1 or SMRT (Polly et al., 2000) . Taken together, these findings and our data support a model whereby elevated SMRT increases the prevalence of repressive complexes such as SMRT-HDAC3, which associate with the promoter/enhancer regions of key antiproliferative target genes, thereby sustaining local histone deacetylation, and shifting the equilibrium point of gene activation resulting in reduced sensitivity to ligand.
The primary cultures used in the study were established from patients with organ-confined disease who had not undergone hormonal manipulation and therefore elevation of SMRT probably occurs relatively early in disease progression, and is sustained through disease progression as a similar elevation was observed in cell lines derived from metastatic lesions. Thus, this lesion may provide therapeutic opportunities for different stages of disease. Epigenetic repression in prostate cancer cells by elevated SMRT will potentially impact on multiple members of the NR superfamily, such as the retinoic acid receptors, peroxisome proliferator-activated receptors and other adopted orphan receptors, resulting in reduced sensitivity to a wide range of dietary-derived macro-and micronutrient ligands. Therefore, individual molecular profiling of early stage cancer disease may identify individuals with more aggressive disease, and those whose disease may be controlled by chemoprevention strategies. Current therapeutic strategies for prostate cancer involve a combination of radiotherapy or/and radical prostatectomy, and eventually androgen ablation. These therapies are aggressive, with many side effects and ultimately the cancer cells escape this control and androgen-independent tumours predominate, which are invariably lethal. The current study has also highlighted the potential to establish novel chemotherapies centred around HDAC inhibitors such as butyrate derivatives, TSA, and suberoylanilide hydroxamic acid (SAHA) (Cohen et al., 2002; Zhu and Otterson 2003; Wang et al., 2004) , in combination with potent dietaryderived compounds, to deliver a more focused and sustained 'anticancer' regimen for androgen-independent disease.
Materials and methods
1a,25(OH) 2 D 3 and HDAC inhibitors 1a,25(OH) 2 D 3 (a generous gift of Dr Milan R Uskokovic, Hoffman La Roche, Nutley, NJ, USA) and TSA (Sigma, Poole, UK) were all stored as 1 mM stock solutions in ethanol at À201C. SB203580, an inhibitor of p38 activation (CalBiochem, Nottingham, UK), was prepared fresh as required as a 1 mM stock solution in DMSO.
Cell culture
Normal prostate epithelial cells (PrEC), as a nontransformed epithelial counterpart were purchased and cultured in PrEGM media (Clonetics, Wokingham, UK) according to the manufacturer's instructions. These cells had a finite lifespan passage time, but during the course of the current study they had a doubling time approximately equal to that of the prostate cancer cell line PC-3 cells (B24 h) obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). PC-3 cells were maintained in RPMI 1640 medium (Gibco-BRL, Paisely, UK), supplemented with 100 U/ml penicillin, 100 mg/ ml streptomycin and 10% fetal bovine serum (Gibco-BRL), and passaged by trypsinizing with 0.25% trypsin-EDTA (Gibco-BRL). All cells were grown at 371C in a humidified atmosphere of 5% CO 2 in air.
Primary cultures
Tissues dissected from radical prostatectomy specimens were processed for primary culture of prostatic epithelial cells according to previously described methods (Peehl, 2004) . None of the patients had received prior chemical, hormonal or radiation therapy. Histological assessment was performed as described (Schmid and McNeal, 1992) . Normal peripheral zone (PZ) and benign prostatic hyperplasia (BPH) were established from tissue with no cancer present in adjacent tissue sections. Cancer cultures (CA) were established from adenocarcinomas of varying Gleason grade listed in Table 1 . Each cell strain was ascribed a number and serially passaged, and cells in secondary or tertiary passages were used for clonal growth assays or RNA isolation. All studies were undertaken in actively proliferating cultures prior to senescence.
Proliferation assays
The action of individual agents alone and in combination was examined using a bioluminescent technique to measure changes in cellular ATP (ViaLight HS, LumiTech, Nottingham, UK) with previously optimized conditions according to the manufacturer's instructions (Rashid et al., 2001a) . Briefly, cells were plated into 96-well, white-walled, tissue culture-treated plates (Fisher Scientific Ltd, Loughborough, UK) (LNCaP, PC-3, and DU-145 at 2 Â 10 3 cells/well; PrEC at 3.5 Â 10 3 cells/well). Growth media containing varying concentrations of TSA, 1a,25(OH) 2 D 3 , or SB203580 was added to a final volume of 100 ml/well and plates were incubated for 96 h, with redosing after 48 h. After the incubation period, 100 ml of nucleotide releasing reagent was added to each well and cells were left for 30 min at room temperature. Liberated ATP was quantitated by adding 20 ml of ATP monitoring reagent (containing luciferin and luciferase) and measuring luminescence with a microplate luminometer (Berthold Detection Systems, Fisher Scientific Ltd). ATP levels were recorded in relative luciferase units and growth inhibition was expressed as a percentage of control.
Clonal proliferation assays were used to evaluate responses of primary cultures to 1a,25(OH) 2 D 3 . Each 60-mm tissue culture dish, coated with collagen and containing 5 ml of serum-free medium (Peehl, 2004) and vehicle or 1a,25(OH) 2 D 3 , was inoculated with 500 cells per dish. After 10 days of incubation, cells were fixed with formalin and stained with crystal violet (Peehl, 2004) . Total cell growth was measured with an Artek image analyser (Dynatech, Chantilly, VA, USA).
Extraction of RNA and RT
PrEC, LNCaP, PC-3, and DU-145 cells were seeded at a density of 2 Â 10 4 /cm 2 and allowed to grow for 36 h to ensure that cells were in mid-exponential phase upon treatment. Cells were harvested or dosed by adding cycloheximide (20 mg/ml) (Sigma-Aldrich), 1a,25(OH) 2 D 3 and/or TSA as indicated with fresh media and incubating for various times. Total RNA was extracted using the GenElute RNA extraction system (SigmaAldrich) according to the manufacturer's instructions. Primary cultures were serially passaged and grown to 80% confluency in standard serum-free medium. Cells were fed and dosed with 1a,25(OH) 2 D 3 as indicated 1 day, prior to isolation of total RNA using the Qiagen RNeasy Midi kit (Qiagen, Palo Alto, CA, USA).
For real-time RT-PCR, cDNA was prepared from 1 mg of total RNA by RT with Mu-MLV (Promega, Southampton, UK) at 421C for 60 min in the presence of 100 mM Tris-HCl, pH 9.0, 500 mM KCl, 2 mM MgCl 2 , 100 pM random hexamers (Pharmacia, Piscataway, NJ, USA), 2 mM dNTP and 20 U RNAsin (Promega) in a 20 ml reaction volume.
Real-time Q-RT-PCR
Expression of specific mRNAs was quantitated using the ABI PRISM 7700 Sequence Detection System. Each sample was amplified in triplicate wells in 25 ml volumes containing 1 Â TaqMan Universal PCR Master Mix (3 mM Mn(OAc) 2 , 200 mM dNTPs, 1.25 U AmpliTaq Gold polymerase, 1.25 units AmpErase UNG), 3.125 pmol FAM-labelled TaqMan probe, and 22.5 pmol primers. All reactions were multiplexed with preoptimized control primers and VIC-labelled probe for 18S ribosomal RNA (PE Biosystems, Warrington, UK). Primer and probe sequences are given in Table 3 . Reactions were cycled as follows: 501C for 2 min, 951C for 10 min; then 44 cycles of 951C for 15 s, and 601C for 1 min.
Data were expressed as C t values (the cycle number at which logarithmic PCR plots cross a calculated threshold line) and used to determine dC t values (dC t ¼ C t of the target gene minus C t of the housekeeping gene). The data were transformed through the equation 2 ÀddCt to give fold changes in gene expression. To exclude potential bias due to averaging of data, all statistics were performed with dC t values. Measurements were carried out a minimum of three times each in triplicate wells for cell lines and once each in triplicate wells for primary material.
cDNA microarray analyses PC-3 cells were seeded at a density of 2 Â 10 4 /cm 2 in T75 flasks and allowed to grow for 36 h. Fresh medium was added with the following treatments: 1a25(OH) 2 D 3 (100 nM) and/or TSA (15 nM) or left untreated as control. After 6 h, total RNA was isolated as indicated above, DNAse treated and resuspended at a concentration of 2.5 mg/ml. From these RNA stocks, 2 ml was used for subsequent generation of radiolabelled probe according to the manufacturer's instructions (Clontech, Wokingham, UK). Clontech Human 1.2 cDNA arrays were incubated overnight with radiolabelled probe. After careful washing the membrane was exposed to film (Kodak, XOMAT) overnight and for 72 h. Images were scanned and the relative difference in the intensity of the signals analysed using the Clontech AtlasImage 1.5 software, which with reference to internal controls, preset limits at which differences in signal intensity and/or fold differences (greater than twofold) were reported.
Repeat experiments involved stripping the membranes (which were checked to ensure zero signal) and reprobing with radiolabelled probes prepared with mRNA isolated from repeat treatments of cells as described above. Tables of differences for each individual and combined treatment were compared to control (Table 2 ). For each of the treatments, the adjusted difference in the intensity of signals for gene targets that were reported in both experiments were averaged to generate the change in the mean adjusted intensity (DMAI). Mean fold differences were only calculated where the basal level of target was detectable. Only genes that were reported as modulated in the same manner in both experiments were included in the results. 
Western immunoblot analysis
PC-3 cells were seeded at a density of 2 Â 10 4 /cm 2 in T75 flasks and allowed to grow for 36 h. Fresh medium was added with the following treatments: 1a25(OH) 2 D 3 (100 nM) and/or TSA (15 nM) or left untreated as control. Whole-cell lysates were prepared at indicated time points and Western immunoblot analysis performed. Briefly, 30 mg of total protein for each sample was electrophoresed through an sodium dodecyl sulphate (SDS)-polyacrylamide gel, transferred onto PVDF membrane (Immobilon-P; Millipore, Bedford, MA, USA) and blocked with TBS-T containing 5% milk powder for 1 h. For detection of GADD45a, a rabbit polyclonal antibody (C-20, Santa Cruz Biotechnology, USA) was diluted 1 : 500. The secondary antibody, donkey anti-rabbit-HRP conjugate (Amersham, UK) was diluted 1 : 1000. Proteins were detected using ECL (Amersham) and autoradiography. To ensure even loading and transfer of protein, membranes were washed for 15 min with TBS-T and incubated with a 1/10 000 dilution of primary mouse monoclonal b-actin antibody (AC-15, SigmaAldrich). An anti-mouse-HRP secondary antibody (Binding Site, UK) was used at 1 : 2000, and signals developed with ECL and autoradiography as described above. To quantify the relative changes in protein levels, densitometry analysis was performed on the autoradiographs and values normalized to b-actin levels.
siRNA to target SMRT SiRNA fragments (22-mers) were generated in vitro using a Dicer generation system according to the manufacturer's protocol (Gene Therapy Systems, San Diego, CA, USA). Briefly, a 650 bp region from the human SMRT gene sequence corresponding to 112-762 was amplified using the following primers containing T7 promoter sequences; FS: 5 0 -gcgtaatacgactcactatagggagacgggctcctggagtaccagc-3 0 and RV: 5 0 -gcgtaatacgactcactatagggagagctccacctggggccccagg-3 0 . This was subsequently cloned into the pGEM T easy vector (Promega), using the multiple cloning sites to allow for sequencing, largescale harvest. Digestion with EcoR1 released a pure concentrated template for in vitro translation with primers containing T7 recognition sequences to generate double-stranded mRNA. This was subsequently cleaved with recombinant human Dicer enzyme to generate a pool of 22-mers that cover the region targeted in the 5 0 prime region of the SMRT gene. Amounts of 500 ng of purified double-stranded RNA 22-mers were transfected into each well (2 Â 10 5 cells/well into 24-well plates) for 12 h. Cells were then left for a further 72 h to allow gene silencing and subsequently treated with 1a,25(OH) 2 D 3 (100 nM) for 6 h and total RNA was harvested and Q-RT-PCR for SMRT and target genes was undertaken as above.
Statistical analysis
The interactions of two compounds were assessed by measuring the mean of either 1a25(OH) 2 D 3 or TSA acting alone or in combination (Campbell et al., 1998) . The mean observed combined effect was compared to the individual effects of the agents added together, using the Student's t-test. The classification of the effects was as follows: strong additive effects were those with an experimental value significantly greater than the predicted value; additive effects were those where the experimental value did not significantly differ from the predicted value; subadditive effects were those where the experimental value was significantly less than the predicated value. All other analyses were compared using the Student's t-test.
